Fig. 2From: Effects of bumetanide on neurodevelopmental impairments in patients with tuberous sclerosis complex: an open-label pilot studyTreatment effect measured by behavioral questionnaires. Left panes show change after treatment and wash-out for (a) ABC Irritability subscale; (c) RBS total score; and (e) SRS-2 total score. Right panes show absolute change per patient after treatment for (b) ABC Irritability subscale; (d) RBS total score; and (f) SRS-2 total scoreBack to article page